BIOMAT Database Logo BIOMAT Database Logo

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions. 2020

Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Clinical Pharmacy, Saarland University, Campus C2 2, 66123, Saarbrücken, Germany.

OBJECTIVE To provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-drug interaction (DDI) modeling. METHODS PBPK models of probenecid and furosemide were developed in PK-Sim®. Drug-dependent parameters and plasma concentration-time profiles following intravenous and oral probenecid and furosemide administration were gathered from literature and used for model development. For model evaluation, plasma concentration-time profiles, areas under the plasma concentration-time curve (AUC) and peak plasma concentrations (Cmax) were predicted and compared to observed data. In addition, the models were applied to predict the outcome of clinical DDI studies. RESULTS The developed models accurately describe the reported plasma concentrations of 27 clinical probenecid studies and of 42 studies using furosemide. Furthermore, application of these models to predict the probenecid-furosemide and probenecid-rifampicin DDIs demonstrates their good performance, with 6/7 of the predicted DDI AUC ratios and 4/5 of the predicted DDI Cmax ratios within 1.25-fold of the observed values, and all predicted DDI AUC and Cmax ratios within 2.0-fold. CONCLUSIONS Whole-body PBPK models of probenecid and furosemide were built and evaluated, providing useful tools to support the investigation of transporter mediated DDIs.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000084342 Drug Elimination Routes Various processes through which administered drugs are discharged from the body. Drug Clearance,Drug Clearance Routes,Drug Elimination,Drug Excretion,Drug Excretion Routes,Drug Clearance Route,Drug Elimination Route,Drug Excretion Route,Excretion Route, Drug,Excretion Routes, Drug
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
October 2021, Pharmaceutical research,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone.
February 2022, CPT: pharmacometrics & systems pharmacology,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.
June 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions.
January 2021, Current drug metabolism,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
April 2017, CPT: pharmacometrics & systems pharmacology,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically-based pharmacokinetic models to predict drug exposure during pregnancy.
March 2024, Annales pharmaceutiques francaises,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.
March 2015, Drug metabolism and disposition: the biological fate of chemicals,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
May 2020, Clinical pharmacology and therapeutics,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
August 2017, European journal of drug metabolism and pharmacokinetics,
Hannah Britz, and Nina Hanke, and Mitchell E Taub, and Ting Wang, and Bhagwat Prasad, and Éric Fernandez, and Peter Stopfer, and Valerie Nock, and Thorsten Lehr
Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.
February 2009, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!